Application | Comment | Organism |
---|---|---|
drug development | MurG is a target for drug development to treat diseases caused by Clostridium difficile, an etiologic agent of a variety of gastrointestinal diseases in humans including mild sporadic diarrhea and severe life-threatening pseudomembranous colitis | Clostridioides difficile |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(1R,3R,3aS,6aR)-1-{[2-({[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl] methyl}amino)-2-oxoethyl]carbamoyl}-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrol-2-ium | - |
Clostridioides difficile | |
(4R,4aR,5aS,6R,12aS)-4-(dimethylamino)-1,5,10,12,12a-pentahydroxy-6-methyl-3,11-dioxo-3,4,4a,5,5a,6,11,12a- octahydrotetracene-2-carboxamide | - |
Clostridioides difficile | |
({2-[3-(4-methoxybenzyl)-6-(methoxycarbonyl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-2-oxoethyl}sulfanyl)acetic acid | - |
Clostridioides difficile | |
2-(carboxyethynyl)-3,4-dihydroxybenzoic acid | - |
Clostridioides difficile | |
2-(phosphonooxy)butanoic acid | - |
Clostridioides difficile | |
4-{[(1S,11aS)-5,11-dioxo-7-phenyl-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-1-yl]amino}-4-oxobutanoic acid | - |
Clostridioides difficile | |
5'-deoxy-5'-[(N-{[(2R,3R,4R,5R)-3-(methoxycarbonyl)-5-(2-methoxyphenyl)-2,4-dimethylpyrrolidinium-2-yl]carbonyl}glycyl) amino]uridine | - |
Clostridioides difficile | |
additional information | inhibitor binding mode, molecular modeling, overview | Clostridioides difficile | |
N-({6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl}sulfonyl)-D-glutamic acid | - |
Clostridioides difficile | |
[1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid) | - |
Clostridioides difficile |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Clostridioides difficile | - |
- |
- |
Clostridioides difficile R20291 | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | sMurG uses UDP-N-acetylglucosamine as substrate | Clostridioides difficile | ? | - |
? | |
additional information | sMurG uses UDP-N-acetylglucosamine as substrate | Clostridioides difficile R20291 | ? | - |
? |
Subunits | Comment | Organism |
---|---|---|
More | structure comparison with the enzyme from Escherichia coli, molecular modeling and structure validation, overview | Clostridioides difficile |
Synonyms | Comment | Organism |
---|---|---|
MurG | - |
Clostridioides difficile |
General Information | Comment | Organism |
---|---|---|
additional information | the active site residue Gln298 plays a critical role in ligand-target interactions, other active site residues like Arg168, Ser198, Arg202, Ser269, and His297 also play roles in binding interactions, docking study, and molecular modeling and structure validation, overview | Clostridioides difficile |